Quality of life

Overall condition was assessed at baseline and last visit on the seven-category Patient or Caregiver Global Impression of Change (GIC) scale. The patient’s overall condition improved by at least one category on the seven-category GIC scale. Improvements were based on measures of GIC scores at the last visit.

Lennox-Gastaut syndrome (LGS)

Significantly more LGS patients and caregivers reported improvements on the GIC scale with Epidyolex and clobazam (CLB) than with placebo.¹

analysis subgroup with CLB

80%

vs. placebo
p<0.0001 & p=0.0003

Epidyolex 20 mg/kg/day

76%

vs. placebo
p=0.0005

Epidyolex 10 mg/kg/day

31–46%

Placebo

Dravet syndrome (DS)

Significantly more DS caregivers reported improvements on the GIC scale with Epidyolex and clobazam than with placebo.¹

analysis subgroup with CLB

62–77%

vs. placebo
p=0.0018 and 0.0136

Epidyolex 20 mg/kg/day

73%

vs. placebo
p=0.0009

Epidyolex 10 mg/kg/day

30–41%

Placebo

The post-hoc analysis has been prepared at the request of the CHMP, p-values for this analysis were found to be nominal.

Discover impact on patient lives

Significantly more LGS and DS patients and caregivers reported improvements on the GIC scale with Epidyolex and clobazam than placebo.¹

Read Miquel's story

References

1. Epidyolex Summary of Product Characteristics (Date accessed: 03/09/2020).